1. Home
  2. BMEA vs SEVN Comparison

BMEA vs SEVN Comparison

Compare BMEA & SEVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMEA
  • SEVN
  • Stock Information
  • Founded
  • BMEA 2017
  • SEVN 1986
  • Country
  • BMEA United States
  • SEVN United States
  • Employees
  • BMEA 63
  • SEVN N/A
  • Industry
  • BMEA Biotechnology: Pharmaceutical Preparations
  • SEVN Real Estate Investment Trusts
  • Sector
  • BMEA Health Care
  • SEVN Real Estate
  • Exchange
  • BMEA Nasdaq
  • SEVN Nasdaq
  • Market Cap
  • BMEA 96.9M
  • SEVN 149.0M
  • IPO Year
  • BMEA 2021
  • SEVN N/A
  • Fundamental
  • Price
  • BMEA $1.36
  • SEVN $9.05
  • Analyst Decision
  • BMEA Strong Buy
  • SEVN Strong Buy
  • Analyst Count
  • BMEA 7
  • SEVN 2
  • Target Price
  • BMEA $8.86
  • SEVN $13.50
  • AVG Volume (30 Days)
  • BMEA 1.7M
  • SEVN 160.3K
  • Earning Date
  • BMEA 11-04-2025
  • SEVN 10-27-2025
  • Dividend Yield
  • BMEA N/A
  • SEVN 12.43%
  • EPS Growth
  • BMEA N/A
  • SEVN N/A
  • EPS
  • BMEA N/A
  • SEVN 1.04
  • Revenue
  • BMEA N/A
  • SEVN $29,408,000.00
  • Revenue This Year
  • BMEA N/A
  • SEVN N/A
  • Revenue Next Year
  • BMEA N/A
  • SEVN N/A
  • P/E Ratio
  • BMEA N/A
  • SEVN $8.69
  • Revenue Growth
  • BMEA N/A
  • SEVN N/A
  • 52 Week Low
  • BMEA $1.22
  • SEVN $8.90
  • 52 Week High
  • BMEA $8.99
  • SEVN $13.97
  • Technical
  • Relative Strength Index (RSI)
  • BMEA 40.15
  • SEVN 28.93
  • Support Level
  • BMEA $1.22
  • SEVN $8.91
  • Resistance Level
  • BMEA $1.35
  • SEVN $10.90
  • Average True Range (ATR)
  • BMEA 0.10
  • SEVN 0.30
  • MACD
  • BMEA 0.00
  • SEVN -0.11
  • Stochastic Oscillator
  • BMEA 31.16
  • SEVN 5.28

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.

About SEVN Seven Hills Realty Trust

Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.

Share on Social Networks: